+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Multiple Myeloma Therapeutics - Market Analysis, Trends, and Forecasts

  • ID: 992789
  • Report
  • 150 Pages
  • Global Industry Analysts, Inc
1 of 4

FEATURED COMPANIES

  • Amgen
  • Celgene Corporation
  • Janssen Biotech
  • Juno Therapeutics, Inc.
  • Kesios Therapeutics Ltd.
  • Novartis International Ag
  • MORE
The Multiple Myeloma Therapeutics market worldwide is projected to grow by US$16.3 Billion, driven by a compounded growth of 16.6%. Chemotherapy & Other Drugs, one of the segments analyzed and sized in this study, displays the potential to grow at over 17.3%. The shifting dynamics supporting this growth makes it critical for businesses in this space to keep abreast of the changing pulse of the market. Poised to reach over US$13.8 Billion by the year 2025, Chemotherapy & Other Drugs will bring in healthy gains adding significant momentum to global growth.

Representing the developed world, the United States will maintain a 14.7% growth momentum. Within Europe, which continues to remain an important element in the world economy, Germany will add over US$625.8 Million to the region's size and clout in the next 5 to 6 years. Over US$524 Million worth of projected demand in the region will come from the rest of the European markets. In Japan, Chemotherapy & Other Drugs will reach a market size of US$665.7 Million by the close of the analysis period. As the world’s second largest economy and the new game changer in global markets, China exhibits the potential to grow at 21.2% over the next couple of years and add approximately US$4 Billion in terms of addressable opportunity for the picking by aspiring businesses and their astute leaders.

Presented in visually rich graphics are these and many more need-to-know quantitative data important in ensuring quality of strategy decisions, be it entry into new markets or allocation of resources within a portfolio. Several macroeconomic factors and internal market forces will shape growth and development of demand patterns in emerging countries in Asia-Pacific, Latin America and the Middle East. All research viewpoints presented are based on validated engagements from influencers in the market, whose opinions supersede all other research methodologies.

Competitors identified in this market include:
  • Amgen, Inc.
  • Bristol-Myers Squibb Company
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Janssen Biotech, Inc.
  • Juno Therapeutics, Inc.
  • Kesios Therapeutics Ltd.
  • Novartis International AG
  • Sanofi Genzyme
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Amgen
  • Celgene Corporation
  • Janssen Biotech
  • Juno Therapeutics, Inc.
  • Kesios Therapeutics Ltd.
  • Novartis International Ag
  • MORE

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Global Competitor Market Shares

Multiple Myeloma Therapeutics Competitor Market Share Scenario Worldwide (in %):2019 & 2028

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

TABLE 1: Multiple Myeloma Therapeutics Global Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025

TABLE 2: Multiple Myeloma Therapeutics Global Retrospective Market Scenario in US$ Million by Region/Country: 2009-2017

TABLE 3: Multiple Myeloma Therapeutics Market Share Shift across Key Geographies Worldwide: 2009 VS 2019 VS 2025

TABLE 4: Chemotherapy & Other Drugs (Type) World Market by Region/Country in US$ Million: 2018 to 2025

TABLE 5: Chemotherapy & Other Drugs (Type) Historic Market Analysis by Region/Country in US$ Million: 2009 to 2017

TABLE 6: Chemotherapy & Other Drugs (Type) Market Share Breakdown of Worldwide Sales by Region/Country: 2009 VS 2019 VS 2025

TABLE 7: Radiation (Type) Potential Growth Markets Worldwide in US$ Million:2018 to 2025

TABLE 8: Radiation (Type) Historic Market Perspective by Region/Country in US$ Million:2009 to 2017

TABLE 9: Radiation (Type) Market Sales Breakdown by Region/Country in Percentage: 2009 VS 2019 VS 2025

TABLE 10: Stem Cell Transplant & Supportive Treatment (Type) Geographic Market Spread Worldwide in US$ Million: 2018 to 2025

TABLE 11: Stem Cell Transplant & Supportive Treatment (Type) Region Wise Breakdown of Global Historic Demand in US$ Million: 2009 to 2017

TABLE 12: Stem Cell Transplant & Supportive Treatment (Type) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025

III. MARKET ANALYSIS

GEOGRAPHIC MARKET ANALYSIS

UNITED STATES

Market Facts & Figures

US Multiple Myeloma Therapeutics Market Share (in %) by Company: 2019 & 2025

TABLE 13: United States Multiple Myeloma Therapeutics Market Estimates and Projections in US$ Million by Type: 2018 to 2025

TABLE 14: Multiple Myeloma Therapeutics Market in the United States by Type: A Historic Review in US$ Million for 2009-2017

TABLE 15: United States Multiple Myeloma Therapeutics Market Share Breakdown by Type: 2009 VS 2019 VS 2025

CANADA

TABLE 16: Canadian Multiple Myeloma Therapeutics Market Estimates and Forecasts in US$ Million by Type: 2018 to 2025

TABLE 17: Canadian Multiple Myeloma Therapeutics Historic Market Review by Type in US$ Million: 2009-2017

TABLE 18: Multiple Myeloma Therapeutics Market in Canada: Percentage Share Breakdown of Sales by Type for 2009, 2019, and 2025

JAPAN

TABLE 19: Japanese Market for Multiple Myeloma Therapeutics: Annual Sales Estimates and Projections in US$ Million by Type for the Period 2018-2025

TABLE 20: Multiple Myeloma Therapeutics Market in Japan: Historic Sales Analysis in US$ Million by Type for the Period 2009-2017

TABLE 21: Japanese Multiple Myeloma Therapeutics Market Share Analysis by Type: 2009 VS 2019 VS 2025

CHINA

TABLE 22: Chinese Multiple Myeloma Therapeutics Market Growth Prospects in US$ Million by Type for the Period 2018-2025

TABLE 23: Multiple Myeloma Therapeutics Historic Market Analysis in China in US$ Million by Type: 2009-2017

TABLE 24: Chinese Multiple Myeloma Therapeutics Market by Type: Percentage Breakdown of Sales for 2009, 2019, and 2025

EUROPE

Market Facts & Figures

European Multiple Myeloma Therapeutics Market: Competitor Market Share Scenario (in %) for 2019 & 2025

TABLE 25: European Multiple Myeloma Therapeutics Market Demand Scenario in US$ Million by Region/Country: 2018-2025

TABLE 26: Multiple Myeloma Therapeutics Market in Europe: A Historic Market Perspective in US$ Million by Region/Country for the Period 2009-2017

TABLE 27: European Multiple Myeloma Therapeutics Market Share Shift by Region/Country: 2009 VS 2019 VS 2025

TABLE 28: European Multiple Myeloma Therapeutics Market Estimates and Forecasts in US$ Million by Type: 2018-2025

TABLE 29: Multiple Myeloma Therapeutics Market in Europe in US$ Million by Type: A Historic Review for the Period 2009-2017

TABLE 30: European Multiple Myeloma Therapeutics Market Share Breakdown by Type: 2009 VS 2019 VS 2025

FRANCE

TABLE 31: Multiple Myeloma Therapeutics Market in France by Type: Estimates and Projections in US$ Million for the Period 2018-2025

TABLE 32: French Multiple Myeloma Therapeutics Historic Market Scenario in US$ Million by Type: 2009-2017

TABLE 33: French Multiple Myeloma Therapeutics Market Share Analysis by Type: 2009 VS 2019 VS 2025

GERMANY

TABLE 34: Multiple Myeloma Therapeutics Market in Germany: Recent Past, Current and Future Analysis in US$ Million by Type for the Period 2018-2025

TABLE 35: German Multiple Myeloma Therapeutics Historic Market Analysis in US$ Million by Type: 2009-2017

TABLE 36: German Multiple Myeloma Therapeutics Market Share Breakdown by Type: 2009 VS 2019 VS 2025

ITALY

TABLE 37: Italian Multiple Myeloma Therapeutics Market Growth Prospects in US$ Million by Type for the Period 2018-2025

TABLE 38: Multiple Myeloma Therapeutics Historic Market Analysis in Italy in US$ Million by Type: 2009-2017

TABLE 39: Italian Multiple Myeloma Therapeutics Market by Type: Percentage Breakdown of Sales for 2009, 2019, and 2025

UNITED KINGDOM

TABLE 40: United Kingdom Market for Multiple Myeloma Therapeutics: Annual Sales Estimates and Projections in US$ Million by Type for the Period 2018-2025

TABLE 41: Multiple Myeloma Therapeutics Market in the United Kingdom: Historic Sales Analysis in US$ Million by Type for the Period 2009-2017

TABLE 42: United Kingdom Multiple Myeloma Therapeutics Market Share Analysis by Type: 2009 VS 2019 VS 2025

SPAIN

TABLE 43: Spanish Multiple Myeloma Therapeutics Market Estimates and Forecasts in US$ Million by Type: 2018 to 2025

TABLE 44: Spanish Multiple Myeloma Therapeutics Historic Market Review by Type in US$ Million: 2009-2017

TABLE 45: Multiple Myeloma Therapeutics Market in Spain: Percentage Share Breakdown of Sales by Type for 2009, 2019, and 2025

RUSSIA

TABLE 46: Russian Multiple Myeloma Therapeutics Market Estimates and Projections in US$ Million by Type: 2018 to 2025

TABLE 47: Multiple Myeloma Therapeutics Market in Russia by Type: A Historic Review in US$ Million for 2009-2017

TABLE 48: Russian Multiple Myeloma Therapeutics Market Share Breakdown by Type: 2009 VS 2019 VS 2025

REST OF EUROPE

TABLE 49: Rest of Europe Multiple Myeloma Therapeutics Market Estimates and Forecasts in US$ Million by Type: 2018-2025

TABLE 50: Multiple Myeloma Therapeutics Market in Rest of Europe in US$ Million by Type: A Historic Review for the Period 2009-2017

TABLE 51: Rest of Europe Multiple Myeloma Therapeutics Market Share Breakdown by Type: 2009 VS 2019 VS 2025

ASIA-PACIFIC

TABLE 52: Asia-Pacific Multiple Myeloma Therapeutics Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025

TABLE 53: Multiple Myeloma Therapeutics Market in Asia-Pacific: Historic Market Analysis in US$ Million by Region/Country for the Period 2009-2017

TABLE 54: Asia-Pacific Multiple Myeloma Therapeutics Market Share Analysis by Region/Country: 2009 VS 2019 VS 2025

TABLE 55: Multiple Myeloma Therapeutics Market in Asia-Pacific by Type: Estimates and Projections in US$ Million for the Period 2018-2025

TABLE 56: Asia-Pacific Multiple Myeloma Therapeutics Historic Market Scenario in US$ Million by Type: 2009-2017

TABLE 57: Asia-Pacific Multiple Myeloma Therapeutics Market Share Analysis by Type: 2009 VS 2019 VS 2025

AUSTRALIA

TABLE 58: Multiple Myeloma Therapeutics Market in Australia: Recent Past, Current and Future Analysis in US$ Million by Type for the Period 2018-2025

TABLE 59: Australian Multiple Myeloma Therapeutics Historic Market Analysis in US$ Million by Type: 2009-2017

TABLE 60: Australian Multiple Myeloma Therapeutics Market Share Breakdown by Type: 2009 VS 2019 VS 2025

INDIA

TABLE 61: Indian Multiple Myeloma Therapeutics Market Estimates and Forecasts in US$ Million by Type: 2018 to 2025

TABLE 62: Indian Multiple Myeloma Therapeutics Historic Market Review by Type in US$ Million: 2009-2017

TABLE 63: Multiple Myeloma Therapeutics Market in India: Percentage Share Breakdown of Sales by Type for 2009, 2019, and 2025

SOUTH KOREA

TABLE 64: Multiple Myeloma Therapeutics Market in South Korea: Recent Past, Current and Future Analysis in US$ Million by Type for the Period 2018-2025

TABLE 65: South Korean Multiple Myeloma Therapeutics Historic Market Analysis in US$ Million by Type: 2009-2017

TABLE 66: Multiple Myeloma Therapeutics Market Share Distribution in South Korea by Type: 2009 VS 2019 VS 2025

REST OF ASIA-PACIFIC

TABLE 67: Rest of Asia-Pacific Market for Multiple Myeloma Therapeutics: Annual Sales Estimates and Projections in US$ Million by Type for the Period 2018-2025

TABLE 68: Multiple Myeloma Therapeutics Market in Rest of Asia-Pacific: Historic Sales Analysis in US$ Million by Type for the Period 2009-2017

TABLE 69: Rest of Asia-Pacific Multiple Myeloma Therapeutics Market Share Analysis by Type: 2009 VS 2019 VS 2025

LATIN AMERICA

TABLE 70: Latin American Multiple Myeloma Therapeutics Market Trends by Region/Country in US$ Million: 2018-2025

TABLE 71: Multiple Myeloma Therapeutics Market in Latin America in US$ Million by Region/Country: A Historic Perspective for the Period 2009-2017

TABLE 72: Latin American Multiple Myeloma Therapeutics Market Percentage Breakdown of Sales by Region/Country: 2009, 2019, and 2025

TABLE 73: Latin American Multiple Myeloma Therapeutics Market Growth Prospects in US$ Million by Type for the Period 2018-2025

TABLE 74: Multiple Myeloma Therapeutics Historic Market Analysis in Latin America in US$ Million by Type: 2009-2017

TABLE 75: Latin American Multiple Myeloma Therapeutics Market by Type: Percentage Breakdown of Sales for 2009, 2019, and 2025

ARGENTINA

TABLE 76: Argentinean Multiple Myeloma Therapeutics Market Estimates and Forecasts in US$ Million by Type: 2018-2025

TABLE 77: Multiple Myeloma Therapeutics Market in Argentina in US$ Million by Type: A Historic Review for the Period 2009-2017

TABLE 78: Argentinean Multiple Myeloma Therapeutics Market Share Breakdown by Type: 2009 VS 2019 VS 2025

BRAZIL

TABLE 79: Multiple Myeloma Therapeutics Market in Brazil by Type: Estimates and Projections in US$ Million for the Period 2018-2025

TABLE 80: Brazilian Multiple Myeloma Therapeutics Historic Market Scenario in US$ Million by Type: 2009-2017

TABLE 81: Brazilian Multiple Myeloma Therapeutics Market Share Analysis by Type: 2009 VS 2019 VS 2025

MEXICO

TABLE 82: Multiple Myeloma Therapeutics Market in Mexico: Recent Past, Current and Future Analysis in US$ Million by Type for the Period 2018-2025

TABLE 83: Mexican Multiple Myeloma Therapeutics Historic Market Analysis in US$ Million by Type: 2009-2017

TABLE 84: Mexican Multiple Myeloma Therapeutics Market Share Breakdown by Type: 2009 VS 2019 VS 2025

REST OF LATIN AMERICA

TABLE 85: Rest of Latin America Multiple Myeloma Therapeutics Market Estimates and Projections in US$ Million by Type: 2018 to 2025

TABLE 86: Multiple Myeloma Therapeutics Market in Rest of Latin America by Type: A Historic Review in US$ Million for 2009-2017

TABLE 87: Rest of Latin America Multiple Myeloma Therapeutics Market Share Breakdown by Type: 2009 VS 2019 VS 2025

MIDDLE EAST

TABLE 88: The Middle East Multiple Myeloma Therapeutics Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025

TABLE 89: Multiple Myeloma Therapeutics Market in the Middle East by Region/Country in US$ Million: 2009-2017

TABLE 90: The Middle East Multiple Myeloma Therapeutics Market Share Breakdown by Region/Country: 2009, 2019, and 2025

TABLE 91: The Middle East Multiple Myeloma Therapeutics Market Estimates and Forecasts in US$ Million by Type: 2018 to 2025

TABLE 92: The Middle East Multiple Myeloma Therapeutics Historic Market by Type in US$ Million: 2009-2017

TABLE 93: Multiple Myeloma Therapeutics Market in the Middle East: Percentage Share Breakdown of Sales by Type for 2009, 2019, and 2025

IRAN

TABLE 94: Iranian Market for Multiple Myeloma Therapeutics: Annual Sales Estimates and Projections in US$ Million by Type for the Period 2018-2025

TABLE 95: Multiple Myeloma Therapeutics Market in Iran: Historic Sales Analysis in US$ Million by Type for the Period 2009-2017

TABLE 96: Iranian Multiple Myeloma Therapeutics Market Share Analysis by Type: 2009 VS 2019 VS 2025

ISRAEL

TABLE 97: Israeli Multiple Myeloma Therapeutics Market Estimates and Forecasts in US$ Million by Type: 2018-2025

TABLE 98: Multiple Myeloma Therapeutics Market in Israel in US$ Million by Type: A Historic Review for the Period 2009-2017

TABLE 99: Israeli Multiple Myeloma Therapeutics Market Share Breakdown by Type: 2009 VS 2019 VS 2025

SAUDI ARABIA

TABLE 100: Saudi Arabian Multiple Myeloma Therapeutics Market Growth Prospects in US$ Million by Type for the Period 2018-2025

TABLE 101: Multiple Myeloma Therapeutics Historic Market Analysis in Saudi Arabia in US$ Million by Type: 2009-2017

TABLE 102: Saudi Arabian Multiple Myeloma Therapeutics Market by Type: Percentage Breakdown of Sales for 2009, 2019, and 2025

UNITED ARAB EMIRATES

TABLE 103: Multiple Myeloma Therapeutics Market in the United Arab Emirates: Recent Past, Current and Future Analysis in US$ Million by Type for the Period 2018-2025

TABLE 104: United Arab Emirates Multiple Myeloma Therapeutics Historic Market Analysis in US$ Million by Type: 2009-2017

TABLE 105: Multiple Myeloma Therapeutics Market Share Distribution in United Arab Emirates by Type: 2009 VS 2019 VS 2025

REST OF MIDDLE EAST

TABLE 106: Multiple Myeloma Therapeutics Market in Rest of Middle East: Recent Past, Current and Future Analysis in US$ Million by Type for the Period 2018-2025

TABLE 107: Rest of Middle East Multiple Myeloma Therapeutics Historic Market Analysis in US$ Million by Type: 2009-2017

TABLE 108: Rest of Middle East Multiple Myeloma Therapeutics Market Share Breakdown by Type: 2009 VS 2019 VS 2025

AFRICA

TABLE 109: African Multiple Myeloma Therapeutics Market Estimates and Projections in US$ Million by Type: 2018 to 2025

TABLE 110: Multiple Myeloma Therapeutics Market in Africa by Type: A Historic Review in US$ Million for 2009-2017

TABLE 111: African Multiple Myeloma Therapeutics Market Share Breakdown by Type: 2009 VS 2019 VS 2025

IV. COMPETITION

AMGEN

BRISTOL-MYERS SQUIBB COMPANY

CELGENE CORPORATION

JANSSEN BIOTECH

JUNO THERAPEUTICS, INC.

KESIOS THERAPEUTICS LTD.

NOVARTIS INTERNATIONAL AG

SANOFI GENZYME

V. CURATED RESEARCH

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • Amgen
  • Celgene Corporation
  • Janssen Biotech
  • Juno Therapeutics, Inc.
  • Kesios Therapeutics Ltd.
  • Novartis International Ag
  • MORE
Multiple Myeloma, a lethal but less common type of blood cancer results in eventual patient relapses even after therapy, and is universally considered as fatal. More than 181,000 individuals suffered from the condition across major regions worldwide, including the US, EU, and Japan in the year 2010, with an estimated 52,000 new cases diagnosed during the year. The condition primarily affects the aged, given the average age of disease onset at around 70 years. Stem cell therapy has been available for treating the condition for several years, and novel drugs that forayed into the market over the years have largely been effective. However, the stem cell transplantation has been more fruitful in younger patient population, and high unmet needs existed for long in high-risk patients. The subsequent launch of new drug agents, such as thalomide, bortezomib, and lenalidomide have succeeded in making a substantial impact on the treatment outcomes in patients of all age groups.

The US represents the largest regional market for multiple myeloma therapeutics worldwide, as stated by the new market research report on Multiple Myeloma Therapeutics. Europe remains the second largest market for multiple myleoma therapeutics worldwide. However, Rest of World, which includes markets such as Canada, Asia-Pacific, Latin America, Africa, and the Middle East, is forecast to garner the fastest growth during the analysis period. Japanese market is projected to tread at a compounded annual growth rate of close to 10% during the analysis period.

Revlimid’s approval for use as a drug in the first line treatment of multiple myeloma has sparked a new momentum for the sales of this drug. Consequently, Revlimid is expected to cannibalize significant share of Velcade in the myeloma therapy market in value terms as well as in terms of the drug’s share in number of patients using the drug. However, the cannibalizing effect is expected to be more profound in case of Thalomid when compared to Velcade. Despite this threat, sales of Velcade and Revlimid are expected to increase, specifically in the patient segment with relapsed/refractory forms of myeloma.

Major players profiled in the report include Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, F. Hoffmann-La Roche Ltd, Genentech Inc., Janssen Biotech Inc, Millennium Pharmaceuticals, Seattle Genetics, Ziopharm Oncology Inc., among others.

The research report titled “Multiple Myeloma Therapeutics: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of the multiple myeloma therapeutics markets, current market trends, key growth drivers, recent product approvals, recent industry activity, and profiles of major/niche global as well as regional market participants. The report provides annual sales estimates and projections for Multiple Myeloma Therapeutics market for the years 2009 through 2017 for the following geographic markets - US, Japan, Europe, and Rest of World. Also, a six-year (2003-2008) historic analysis is provided for additional perspective.

Global Industry Analysts ©
Note: Product cover images may vary from those shown
5 of 4
  • Amgen
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Janssen Biotech
  • Juno Therapeutics, Inc.
  • Kesios Therapeutics Ltd.
  • Novartis International Ag
  • Sanofi Genzyme
Note: Product cover images may vary from those shown
Adroll
adroll